medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 4

<< Back Next >>

Ann Hepatol 2016; 15 (4)

CUL4B, NEDD4, and UGT1AS involve in the TGF-β signalling in hepatocellular carcinoma

Qu Z, Li D, Xu H, Zhang R, Li B, Sun C, Dong W, Zhang Y

Language: English
References: 42
Page: 568-576
PDF size: 255.75 Kb.


ABSTRACT

Introduction and Aim. TGF-β signalling is involved in pathogenesis and progress of hepatocellular carcinoma (HCC). This bioinformatics study consequently aims to determine the underlying molecular mechanism of TGF-β activation in HCC cells. Material and methods. Dataset GSE10393 was downloaded from Gene Expression Omnibus, including 2 Huh-7 (HCC cell line) samples treated by TGF-β (100 pmol/L, 48 h) and 2 untreated samples. Differentially expressed genes (DEGs) were screened using Limma package (false discovery rate ‹ 0.05 and |log2 fold change| › 1.5), and then enrichment analyses of function, pathway, and disease were performed. In addition, protein-protein interaction (PPI) network was constructed based on the PPI data from multiple databases including INACT, MINT, BioGRID, UniProt, BIND, BindingDB, and SPIKE databases. Transcription factor (TF)-DEG pairs (Bonferroni adjusted p-value ‹ 0.01) from ChEA database and DEG-DEG pairs were used to construct TF-DEG regulatory network. Furthermore, TF-pathway-DEG complex network was constructed by integrating DEG-DEG pairs, TF-DEG pairs, and DEG-pathway pairs. Results. Totally, 209 DEGs and 30 TFs were identified. The DEGs were significantly enriched in adhesion-related functions. PPI network indicted hub genes such as CUL4B and NEDD4. According to the TF-DEG regulatory network, the two hub genes were targeted by SMAD2, SMAD3, and HNF4A. Besides, the 11 pathways in TF-pathway-DEG network were mainly enriched by UGT1A family and CYP3A7, which were predicted to be regulated by SMAD2, SMAD3, SOX2, TP63, and HNF4A. Conclusions. TGF-β might influence biological processes of HCC cells via SMAD2/SMAD3-NEDD4, HNF4A-CUL4B/NEDD4, SOX2/TP63/HNF4A-CYP3A7, and SMAD2/SMAD3/SOX2/TP63/HNF4A-UGT1As regulatory pathways.


REFERENCES

  1. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008; 48: 2047-63.

  2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-73.

  3. Andreou A, Vauthey JN, Cherqui D, Zimmitti G, Ribero D, Truty MJ, Wei SH, et al. Improved long-term survival after major resection for hepatocellular carcinoma: a multicenter analysis based on a new definition of major hepatectomy. J Gastrointest Surg 2013; 17: 66-77.

  4. Nelson WJ, Nusse R. Convergence of Wnt, β-catenin, and cadherin pathways. Science 2004; 303: 1483-7.

  5. Giannelli G, Villa E, Lahn M. Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma. Cancer Res 2014; 74: 1890-4.

  6. Meindl-Beinker NM, Matsuzaki K, Dooley S. TGF-beta signaling in onset and progression of hepatocellular carcinoma. Dig Dis 2012; 30: 514-23.

  7. Katsuno Y, Lamouille S, Derynck R. TGF-beta signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 2013; 25: 76-84.

  8. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet J-P, Chiang DY, Villanueva A, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009; 69: 7385-92.

  9. Feng T, Dzieran J, Gu X, Marhenke S, Vogel A, Machida K, Weiss TS, et al. Smad7 regulates compensatory hepatocyte proliferation in damaged mouse liver and positively relates to better clinical outcome in human hepatocellular carcinoma. Clin Sci (Lond) 2015; 128: 761-74.

  10. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.

  11. Smyth GK. Limma: linear models for microarray data, in Bioinformatics and computational biology solutions using R and Bioconductor. Springer; 2005, p. 397-420.

  12. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 57: 289-300.

  13. Tweedie S, Ashburner M, Falls K, Leyland P, Mcquilton P, Marygold S, Millburn G, et al. FlyBase: enhancing Drosophila gene ontology annotations. Nucleic Acid Res 2009; 37: D555-D559.

  14. Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 2012; 16: 284-7.

  15. Yu G, Wang L-G. Disease Ontology Semantic and Enrichment analysis. 2013.

  16. Grega M, Bryk D, Napora M, Gusta M, INACT-INDECT advanced image cataloguing tool, in Multimedia Communications, Services and Security. Springer; 2011, p. 28-36.

  17. Chatr-Aryamontri A, Ceol A, Palazzi LM, Nardelli G, Schneider MV, Castagnoli L, Cesareni G. MINT: the Molecular INTeraction database. Nucleic Acid Res 2007; 35: D572-D574.

  18. Stark C, Breitkreutz B-J, Chatr-Aryamontri A, Boucher L, Oughtred R, Livstone MS, Nixon J, et al. The BioGRID interaction database: 2011 update. Nucleic Acid Res 2011; 39: D698-D704.

  19. Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, Ferro S, Gasteiger E, et al. UniProt: the universal protein knowledgebase. Nucleic Acid Res 2004; 32: D115-D119.

  20. Bader GD, Betel D, Hogue CW. BIND: the biomolecular interaction network database. Nucleic Acid Res 2003; 31: 248-50.

  21. Wassermann AM, Bajorath J. BindingDB and ChEMBL: online compound databases for drug discovery. Expert Opin Drug Discov 2011; 6: 683-7.

  22. Paz A, Brownstein Z, Ber Y, Bialik S, David E, Sagir D, Ulitsky I, et al. SPIKE: a database of highly curated human signaling pathways. Nucleic Acid Res 2011; 39: D793-D799.

  23. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-504.

  24. Su G, Kuchinsky A, Morris JH, Meng F. GLay: community structure analysis of biological networks. Bioinformatics 2010; 26: 3135-7.

  25. Morris JH, Apeltsin L, Newman AM, Baumbach J, Wittkop T, Su G, Bader GD, et al. clusterMaker: a multi-algorithm clustering plugin for Cytoscape. BMC bioinformatics 2011; 12: 436.

  26. Lachmann A, Xu H, Krishnan J, Berger SI, Mazloom AR, Ma’ayan A. ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics 2010; 26: 2438-44.

  27. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75: 800-2.

  28. Cavallaro U, Christofori G. Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. Biochim Biophys Acta 2001; 1552: 39-45.

  29. Fransvea E, Mazzocca A, Antonaci S, Giannelli G. Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology 2009; 49: 839-50.

  30. Yang Y-A, Zhang G-M, Feigenbaum L, Zhang YE. Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer cell 2006; 9: 445-57.

  31. Remy I, Montmarquette A, Michnick SW. PKB/Akt modulates TGF-b signalling through a direct interaction with Smad3. Nat Cell Biol 2004; 6: 358-65.

  32. Wendt MK, Allington TM, Schiemann WP. Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol 2009; 5: 1145-68.

  33. Ceballos MP, Parody JP, Alvarez MDL, Ingaramo PI, Carnovale CE, Carrillo MC. Interferon-á2b and transforming growth factor-b1 treatments on HCC cell lines: Are Wnt/b-catenin pathway and Smads signaling connected in hepatocellular carcinoma? Biochem Pharmacol 2011; 82: 1682-91.

  34. Kuratomi G, Komuro A, Goto K, Shinozaki M, Miyazawa K, Miyazono K, Imamura T. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor. Biochem J 2005; 386: 461-70.

  35. Watt AJ, Garrison WD, Duncan SA. HNF4: a central regulator of hepatocyte differentiation and function. Hepatology 2003; 37: 1249-53.

  36. Yasui K, Arii S, Zhao C, Imoto I, Ueda M, Nagai H, Emi M, et al. TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology 2002; 35: 1476-84.

  37. Sun C, Sun L, Li Y, Kang X, Zhang S, Liu Y. Sox2 expression predicts poor survival of hepatocellular carcinoma patients and it promotes liver cancer cell invasion by activating Slug. Med Oncol 2013; 30: 1-10.

  38. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dötsch V, Andrews NC, et al. p63, a p53 Homolog at 3q27–29, Encodes Multiple Products with Transactivating, Death-Inducing, and Dominant-Negative Activities. Mol Cell 1998; 2: 305-16.

  39. Moll UM, Slade N. p63 and p73: Roles in Development and Tumor Formation 11 National Cancer Institute. Mol Cancer Res 2004; 2: 371-86.

  40. Tsunedomi R, Iizuka N, Hamamoto Y, Uchimura S, Miyamoto T, Tamesa T, Okada T, et al. Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma. Int J Oncol 2005; 27: 661-7.

  41. Kivist KT, Bookjans G, Fromm MF, Griese EU, Mnzel P, Kroemer HK. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 1996; 42: 387-9.

  42. Tseng CS, Tang KS, Lo HW, Ker CG, Teng HC, Huang CS. UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma risk and onset age. Am J Gastroenterol 2005; 100: 1758-63.




2020     |     www.medigraphic.com